




# POSIBLES USOS TERAPÉUTICOS



[Bibliografía científica .....](#)

[Aspectos sobre el uso terapéutico del cannabis .....](#)

[Otras publicaciones .....](#)



## LITERATURA CIENTÍFICA

**Fuente:** PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: <https://www.ncbi.nlm.nih.gov/pubmed/>

**Detalles de búsqueda:** ("medical marijuana/therapeutic use"[MeSH Major Topic] AND ("legal"[All Fields] OR "legalism"[All Fields] OR "legalities"[All Fields] OR "legality"[All Fields] OR "legalization"[All Fields] OR "legalize"[All Fields] OR "legalized"[All Fields] OR "legalizes"[All Fields] OR "legalizing"[All Fields] OR "legally"[All Fields]) AND "humans"[MeSH Terms]) AND ((y\_5[Filter]) AND (review[Filter] OR systematicreview[Filter]))

**NOTA - Debido al altísimo nº de los resultados obtenido, las Novedades resaltadas en color verde recogen mayoritariamente entradas formadas por revisiones, revisiones sistemáticas.**

### 2022

[Aebischer JH, Dieckmann NF, Jones KD, St John AW. Chronic Pain Clinical and Prescriptive Practices in the Cannabis Era. Pain Manag Nurs. abril de 2022;23\(2\):109-21.](#)

[Khoury R, Maliha P, Ibrahim R. Cannabis Use and Misuse in Older Adults. Clin Geriatr Med. febrero de 2022;38\(1\):67-83.](#)

[Slawek DE, Curtis SA, Arnsten JH, Cunningham CO. Clinical Approaches to Cannabis: A Narrative Review. Med Clin North Am. enero de 2022;106\(1\):131-52.](#)

### 2021

[Nguyen AX, Wu AY. Cannabis and the Cornea. Ocul Immunol Inflamm. 4 de julio de 2021;29\(5\):1023-8.](#)

[Hordowicz M, Klimkiewicz A, Jarosz J, Wysocka M, Jastrzębska M. Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review. Drug Alcohol Depend. 1 de abril de 2021;221:108652.](#)

[Anand U, Pacchetti B, Anand P, Sodergren MH. Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. Pain Manag. abril de 2021;11\(4\):395-403.](#)

[Mechtler LL, Gengo FM, Bargnes VH. Cannabis and Migraine: It's Complicated. Curr Pain Headache Rep. 25 de febrero de 2021;25\(3\):16.](#)

[Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Cannabis: A Toxin-Producing Plant with Potential](#)



[Therapeutic Uses. Toxins \(Basel\). 5 de febrero de 2021;13\(2\):117.](#)

[Stewart C, Fong Y. Perioperative Cannabis as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence. JAMA Surg. 1 de febrero de 2021;156\(2\):181-90.](#)

[Melaragno JI, Bowman LJ, Park JM, Lourenco LM, Doligalski CT, Brady BL, et al. The Clinical Conundrum of Cannabis: Current Practices and Recommendations for Transplant Clinicians: An Opinion of the Immunology/Transplantation PRN of the American College of Clinical Pharmacy. Transplantation. 1 de febrero de 2021;105\(2\):291-9.](#)

[Pasha AK, Clements CY, Reynolds CA, Lopez MK, Lugo CA, Gonzalez Y, et al. Cardiovascular Effects of Medical Marijuana: A Systematic Review. Am J Med. febrero de 2021;134\(2\):182-93.](#)

[Charitos IA, Gagliano-Candela R, Santacroce L, Bottalico L. The Cannabis Spread throughout the Continents and its Therapeutic Use in History. Endocr Metab Immune Disord Drug Targets. 2021;21\(3\):407-17.](#)

## 2020

[Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. Sports Health. diciembre de 2020;12\(6\):540-6.](#)

[Adamson M, Di Giovanni B, Delgado DH. The positive and negative cardiovascular effects of cannabis. Expert Rev Cardiovasc Ther. diciembre de 2020;18\(12\):905-17.](#)

[Gressler LE, Baltz AP, Costantino RC, Slejko JF, Onukwugha E. Exploring the Use of State Medical Cannabis Legislation as a Proxy for Medical Cannabis Use Among Patients Receiving Chemotherapy. Curr Treat Options Oncol. 19 de noviembre de 2020;22\(1\):1.](#)

[Alharbi YN. Current legal status of medical marijuana and cannabidiol in the United States. Epilepsy Behav. noviembre de 2020;112:107452.](#)

[Vlad RA, Hancu G, Ciurba A, Antonoaea P, Rédei EM, Todoran N, et al. Cannabidiol - therapeutic and legal aspects. Pharmazie. 1 de octubre de 2020;75\(10\):463-9.](#)

[Page RL, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, et al. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 8 de septiembre de 2020;142\(10\):e131-52.](#)

[Yeung M, Wroot H, Charnock C, Forbes C, Lafay-Cousin L, Schulte F. Cannabis use in pediatric cancer patients: what are they reading? A review of the online literature. Support Care Cancer. agosto de 2020;28\(8\):3503-15.](#)



[Fragoso YD, Carra A, Macias MA. Cannabis and multiple sclerosis. Expert Rev Neurother. agosto de 2020;20\(8\):849-54.](#)

[Gotfried J, Naftali T, Schey R. Role of Cannabis and Its Derivatives in Gastrointestinal and Hepatic Disease. Gastroenterology. julio de 2020;159\(1\):62-80.](#)

[Areesantichai C, Perngparn U, Pilley C. Current cannabis-related situation in the Asia-Pacific region. Curr Opin Psychiatry. julio de 2020;33\(4\):352-9.](#)

[Meng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H. Cannabis and cannabinoids in cancer pain management. Curr Opin Support Palliat Care. junio de 2020;14\(2\):87-93.](#)

[Stetten N, Pomeranz J, Moorhouse M, Yurasek A, Blue AV. The level of evidence of medical marijuana use for treating disabilities: a scoping review. Disabil Rehabil. mayo de 2020;42\(9\):1190-201.](#)

[Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: A review. J Am Acad Dermatol. mayo de 2020;82\(5\):1205-12.](#)

[Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 15 de abril de 2020;411:116717.](#)

[Kleeman-Forsthuber LT, Dennis DA, Jennings JM. Medicinal Cannabis in Orthopaedic Practice. J Am Acad Orthop Surg. 1 de abril de 2020;28\(7\):268-77.](#)

[Greger J, Bates V, Mechtler L, Gengo F. A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents. J Clin Pharmacol. abril de 2020;60\(4\):432-8.](#)

[Cohen J, Wei Z, Phang J, Laprairie RB, Zhang Y. Cannabinoids as an Emerging Therapy for Posttraumatic Stress Disorder and Substance Use Disorders. J Clin Neurophysiol. enero de 2020;37\(1\):28-34.](#)

[Carter A. A North American History of Cannabis Use in the Treatment of Epilepsy. J Clin Neurophysiol. enero de 2020;37\(1\):35-8.](#)

[Botsford SL, Yang S, George TP. Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential. Am J Addict. enero de 2020;29\(1\):9-26.](#)

## 2019

[Maher DP, Carr DB, Hill K, McGeeney B, Weed V, Jackson WC, et al. Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical](#)



[Science. Pain Med. 1 de noviembre de 2019;20\(11\):2311-23.](#)

[Appendino JP, Boelman C, Brna PM, Burneo JG, Claassen CS, Connolly MB, et al. Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada. Can J Neurol Sci. noviembre de 2019;46\(6\):645-52.](#)

[Singh V, Zarrabi AJ, Curseen KA, Sniecinski R, Welsh JW, McKenzie-Brown AM, et al. Concerns of Patients With Cancer on Accessing Cannabis Products in a State With Restrictive Medical Marijuana Laws: A Survey Study. J Oncol Pract. octubre de 2019;15\(10\):531-8.](#)

[Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. octubre de 2019;15\(10\):1019-32.](#)

[VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. septiembre de 2019;94\(9\):1840-51.](#)

[Knöss W, van de Velde M, Sandvos C, Cremer-Schaeffer P. Key elements of legal environments for medical use of cannabis in different countries. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. julio de 2019;62\(7\):855-60.](#)

[Banister SD, Arnold JC, Connor M, Glass M, McGregor IS. Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol. ACS Chem Neurosci. 15 de mayo de 2019;10\(5\):2160-75.](#)

[Fitzcharles M-A, Niaki OZ, Hauser W, Hazlewood G, Canadian Rheumatology Association. Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. J Rheumatol. mayo de 2019;46\(5\):532-8.](#)

[Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, et al. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 21 de febrero de 2019;25\(3\):427-35.](#)

[Steele G, Arneson T, Zylla D. A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety. Curr Oncol Rep. 1 de febrero de 2019;21\(1\):10.](#)

[Vasconcelos SC, Silva AO, Moreira MASP, Correia A de SB, Guerra ALAG, Santos ARD, et al. Bioethical analysis to the therapeutic use of Cannabis: Integrative review. Nurs Ethics. febrero de 2019;26\(1\):96-104.](#)

[Burggren AC, Shirazi A, Ginder N, London ED. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. Am J Drug Alcohol Abuse. 2019;45\(6\):563-79.](#)



[Kruger DJ, Kruger JS. Medical Cannabis Users' Comparisons between Medical Cannabis and Mainstream Medicine. J Psychoactive Drugs. marzo de 2019;51\(1\):31-6.](#)

[Papagianni EP, Stevenson CW. Cannabinoid Regulation of Fear and Anxiety: an Update. Curr Psychiatry Rep. 27 de abril de 2019;21\(6\):38.](#)

[Shi Y, Liang D, Bao Y, An R, Wallace MS, Grant I. Recreational marijuana legalization and prescription opioids received by Medicaid enrollees. Drug Alcohol Depend. 01 de 2019;194:13-9.](#)

[Tucker JS, Rodriguez A, Pedersen ER, Seelam R, Shih RA, D'Amico EJ. Greater risk for frequent marijuana use and problems among young adult marijuana users with a medical marijuana card. Drug Alcohol Depend. 01 de 2019;194:178-83.](#)

[Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. enero de 2019;27:383-90.](#)

[The effectiveness of self-directed medical cannabis treatment for pain. Complementary Therapies in Medicine. 1 de octubre de 2019;46:123-30.](#)

## 2018

[Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med. 2018;49:2-6.](#)

[Bruce D, Brady JP, Foster E, Shattell M. Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses. J Altern Complement Med. febrero de 2018;24\(2\):146-53.](#)

[D'Amico EJ, Rodriguez A, Tucker JS, Pedersen ER, Shih RA. Planting the seed for marijuana use: Changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. Drug Alcohol Depend. 01 de 2018;188:385-91.](#)

[Dhadwal G, Kirchof MG. The Risks and Benefits of Cannabis in the Dermatology Clinic. J Cutan Med Surg. abril de 2018;22\(2\):194-9.](#)

[Dutra LM, Parish WJ, Gourdet CK, Wylie SA, Wiley JL. Medical cannabis legalization and state-level prevalence of serious mental illness in the National Survey on Drug Use and Health \(NSDUH\) 2008-2015. Int Rev Psychiatry. 2018;30\(3\):203-15.](#)

[Fitzcharles MA, Eisenberg E. Medical cannabis: A forward vision for the clinician. Eur J Pain. 2018;22\(3\):485-91.](#)



[Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R. Cannabis in liver disorders: a friend or a foe? Eur J Gastroenterol Hepatol. 2018;30\(11\):1283-90.](#)

[Kalla A, Krishnamoorthy PM, Gopalakrishnan A, Figueredo VM. Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample. J Cardiovasc Med \(Hagerstown\). septiembre de 2018;19\(9\):480-4.](#)

[Meacham MC, Ramo DE, Kral AH, Riley ED. Associations between medical cannabis and other drug use among unstably housed women. Int J Drug Policy. 2018;52:45-51.](#)

[Mechcatie E. The Impact of Legalization of Medical and Recreational Marijuana. Am J Nurs. julio de 2018;118\(7\):16.](#)

[Romero-Sandoval EA, Fincham JE, Kolano AL, Sharpe BN, Alvarado-Vázquez PA. Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy. 2018;38\(6\):651-62.](#)

[Sagy I, Peleg-Sagy T, Barski L, Zeller L, Jotkowitz A. Ethical issues in medical cannabis use. Eur J Intern Med. 2018;49:20-2.](#)

[Sandoval Gutiérrez JL. Legalization of Marijuana for Medical Use in Mexico. Open File. Rev Colomb Psiquiatr. junio de 2018;47\(2\):137.](#)

## 2017

[AbdelFattah KR, Edwards CR, Cripps MW, Minshall CT, Phelan HA, Minei JP, et al. Cannabis Use Has Negligible Effects Following Severe Traumatic Injury. J Trauma Nurs. abril de 2017;24\(2\):141-5.](#)

[Hasin DS, Sarvet AL, Cerdà M, Keyes KM, Stohl M, Galea S, et al. US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 1 de junio de 2017;74\(6\):579-88.](#)

[Chan MH, Knoepke CE, Cole ML, McKinnon J, Matlock DD. Colorado Medical Students' Attitudes and Beliefs About Marijuana. J Gen Intern Med. abril de 2017;32\(4\):458-63.](#)

[Evanoff AB, Quan T, Dufault C, Awad M, Bierut LJ. Physicians-in-training are not prepared to prescribe medical marijuana. Drug Alcohol Depend. 01 de 2017;180:151-5.](#)

[Hill KP, Palastro MD. Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts. Polish Archives of Internal Medicine. 30 de 2017;127\(11\):785-9.](#)

[Hoffenberg EJ, Newman H, Collins C, Tarbell S, Leinwand K. Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High. J Pediatr Gastroenterol Nutr. 2017;64\(2\):265-71.](#)



[Hunt PE, Miles J. The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the USA. Curr Top Behav Neurosci. 2017;34:173-98.](#)

[Park J-Y, Wu L-T. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug Alcohol Depend. 01 de 2017;177:1-13.](#)

[Pergam SA, Woodfield MC, Lee CM, Cheng G-S, Baker KK, Marquis SR, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 15 de noviembre de 2017;123\(22\):4488-97.](#)

[Phatak UP, Rojas-Velasquez D, Porto A, Pashankar DS. Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017;64\(2\):261-4.](#)

[Shi Y. Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend. 1 de abril de 2017;173:144-50.](#)

[Subbaraman MS, Kerr WC. Support for marijuana legalization in the US state of Washington has continued to increase through 2016. Drug Alcohol Depend. 01 de 2017;175:205-9.](#)

[Sznitman SR. Do recreational cannabis users, unlicensed and licensed medical cannabis users form distinct groups? Int J Drug Policy. 2017;42:15-21.](#)

[Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34\(11\):1006-17.](#)

[Ullman DF. The Effect of Medical Marijuana on Sickness Absence. Health Econ. 2017;26\(10\):1322-7.](#)

[Weiss SRB, Howlett KD, Baler RD. Building smart cannabis policy from the science up. Int J Drug Policy. 2017;42:39-49.](#)

[Wong SS, Wilens TE. Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics. noviembre de 2017;140\(5\).](#)

## 2016

[Albertson TE, Chenoweth JA, Colby DK, Sutter ME. The Changing Drug Culture: Medical and Recreational Marijuana. FP Essent. febrero de 2016;441:11-7.](#)

[Balon R. The madness of medical marijuana and marijuana legalization. Ann Clin Psychiatry. 2016;28\(4\):229-30.](#)





[Davis JM, Mendelson B, Berkes JJ, Suleta K, Corsi KF, Booth RE. Public Health Effects of Medical Marijuana Legalization in Colorado. Am J Prev Med. marzo de 2016;50\(3\):373-9.](#)

[Kim HS, Monte AA. Colorado Cannabis Legalization and Its Effect on Emergency Care. Ann Emerg Med. 2016;68\(1\):71-5.](#)

[Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction. 2016;111\(6\):973-80.](#)

[Thomasius R, Holtmann M. \[Are protection of minors and cannabis legalization compatible with each other? – The legalization debate from a child and adolescent psychiatric point of view\]. Z Kinder Jugendpsychiatr Psychother. 2016;44\(2\):95-100.](#)

[Wang JB, Ramo DE, Lisha NE, Cataldo JK. Medical marijuana legalization and cigarette and marijuana co-use in adolescents and adults. Drug Alcohol Depend. 1 de septiembre de 2016;166:32-8.](#)

## 2015

[Fischer B, Kuganesan S, Room R. Medical Marijuana programs: implications for cannabis control policy--observations from Canada. Int J Drug Policy. enero de 2015;26\(1\):15-9.](#)

[Goldsmith RS, Targino MC, Fanciullo GJ, Martin DW, Hartenbaum NP, White JM, et al. Medical marijuana in the workplace: challenges and management options for occupational physicians. J Occup Environ Med. mayo de 2015;57\(5\):518-25.](#)

[Hall W. U.S. Policy Responses to Calls for the Medical Use of Cannabis. Yale J Biol Med. septiembre de 2015;88\(3\):257-64.](#)

[Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. JAMA. 20 de enero de 2015;313\(3\):241-2.](#)

[Sznitman SR, Zolotov Y. Cannabis for therapeutic purposes and public health and safety: a systematic and critical review. Int J Drug Policy. enero de 2015;26\(1\):20-9.](#)

[Thomas SP. Complexities emanating from legalization of marijuana. Issues Ment Health Nurs. 2015;36\(9\):657-8.](#)

[Troutt WD, DiDonato MD. Medical Cannabis in Arizona: Patient Characteristics, Perceptions, and Impressions of Medical Cannabis Legalization. J Psychoactive Drugs. octubre de 2015;47\(4\):259-66.](#)

## 2014



[Choo EK, Benz M, Zaller N, Warren O, Rising KL, McConnell KJ. The impact of state medical marijuana legislation on adolescent marijuana use. J Adolesc Health. agosto de 2014;55\(2\):160-6.](#)

[Larriviere DG. Medical marijuana for HIV-associated sensory neuropathy: legal and ethical issues. Continuum \(Minneapolis, Minn\). octubre de 2014;20\(5 Peripheral Nervous System Disorders\):1426-9.](#)



## ASPECTOS SOBRE EL USO TERAPÉUTICO DEL CANNABIS

**Fuente:** PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: <https://www.ncbi.nlm.nih.gov/pubmed/>

**Detalles de búsqueda:** (("cannabis"[MeSH Terms] OR "cannabis"[All Fields]) AND ("drug interactions"[MeSH Terms] OR ("drug"[All Fields] AND "interactions"[All Fields]) OR "drug interactions"[All Fields]) AND "humans"[MeSH Terms]) AND ((y\_5[Filter]) AND (meta-analysis[Filter] OR review[Filter] OR systematicreview[Filter]))

**NOTA - Debido al altísimo nº de los resultados obtenido, las Novedades resaltadas en color verde recogen mayoritariamente entradas formadas por revisiones, revisiones sistemáticas y metaánalisis.**

### 2022

[Janecki M, Graczyk M, Lewandowska AA, Pawlak Ł. Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection. Int J Mol Sci. 10 de abril de 2022;23\(8\):4170.](#)

[Lord S, Hardy J, Good P. Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer? Curr Treat Options Oncol. abril de 2022;23\(4\):514-25.](#)

[Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. Epilepsy Behav. marzo de 2022;128:108577.](#)

[Kolla BP, Hayes L, Cox C, Eatwell L, Deyo-Svendsen M, Mansukhani MP. The Effects of Cannabinoids on Sleep. J Prim Care Community Health. diciembre de 2022;13:21501319221081276.](#)

[Traccis F, Presciuttini R, Pani PP, Sinclair JMA, Leggio L, Agabio R. Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials. Neurosci Biobehav Rev. enero de 2022;132:519-41.](#)

### 2021

[Murkar A, De Koninck J, Merali Z. Cannabinoids: Revealing their complexity and role in central networks of fear and anxiety. Neurosci Biobehav Rev. diciembre de 2021;131:30-46.](#)

[Duarte RA, Dahmer S, Sanguinetti SY, Forde G, Duarte DP, Kobak LF. Medical Cannabis for Headache Pain: a Primer for Clinicians. Curr Pain Headache Rep. 9 de octubre de 2021;25\(10\):64.](#)



[García-Peñas JJ, Gil Nagel-Rein A, Sánchez-Carpintero R, Villanueva-Haba V. Cannabidiol para el tratamiento del síndrome de Lennox-Gastaut y del síndrome de Dravet: recomendaciones de expertos sobre su uso en la práctica clínica en España. Rev Neurol. 10 de septiembre de 2021;73\(S01\):S1-8.](#)

[Brown JD, Rivera Rivera KJ, Hernandez LYC, Doenges MR, Auchey I, Pham T, et al. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. J Clin Pharmacol. agosto de 2021;61 Suppl 2:S37-52.](#)

[Petersen MJ, Bergien SO, Staerk D. A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease-modifying or symptom-alleviating multiple sclerosis drugs. Phytother Res. julio de 2021;35\(7\):3610-31.](#)

[MacCallum CA, Lo LA, Boivin M. «Is medical cannabis safe for my patients?» A practical review of cannabis safety considerations. Eur J Intern Med. julio de 2021;89:10-8.](#)

[Solomon HV, Greenstein AP, DeLisi LE. Cannabis Use in Older Adults: A Perspective. Harv Rev Psychiatry. 1 de junio de 2021;29\(3\):225-33.](#)

[Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Aust J Gen Pract. junio de 2021;50\(6\):345-50.](#)

[Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology. 1 de marzo de 2021;185:108442.](#)

[Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. Interaction of cannabidiol with other antiseizure medications: A narrative review. Seizure. marzo de 2021;86:189-96.](#)

[Melaragno JI, Bowman LJ, Park JM, Lourenco LM, Doligalski CT, Brady BL, et al. The Clinical Conundrum of Cannabis: Current Practices and Recommendations for Transplant Clinicians: An Opinion of the Immunology/Transplantation PRN of the American College of Clinical Pharmacy. Transplantation. 1 de febrero de 2021;105\(2\):291-9.](#)

[Wilson M, Klein T, Bindler RJ, Kaplan L. Shared Decision-Making for Patients Using Cannabis for Pain Symptom Management in the United States. Pain Manag Nurs. febrero de 2021;22\(1\):15-20.](#)

## 2020

[Narouze S, Strand N, Roychoudhury P. Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. Adv Anesth. diciembre de 2020;38:167-88.](#)

[Amaral Silva D, Pate DW, Clark RD, Davies NM, El-Kadi AOS, Löbenberg R. Phytocannabinoid drug-](#)



[drug interactions and their clinical implications. Pharmacol Ther. noviembre de 2020;215:107621.](#)

[Namdar D, Anis O, Poulin P, Koltai H. Chronological Review and Rational and Future Prospects of Cannabis-Based Drug Development. Molecules. 20 de octubre de 2020;25\(20\):E4821.](#)

[Brunetti P, Lo Faro AF, Pirani F, Berretta P, Pacifici R, Pichini S, et al. Pharmacology and legal status of cannabidiol. Ann Ist Super Sanita. septiembre de 2020;56\(3\):285-91.](#)

[Opitz BJ, Ostroff ML, Whitman AC. The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer. J Pharm Pract. agosto de 2020;33\(4\):506-12.](#)

[Kraft B, Stromer W. \[The effects of cannabis and cannabinoids on anesthesia and analgesia during the perioperative period\]. Schmerz. agosto de 2020;34\(4\):314-8.](#)

[Dharmapuri S, Miller K, Klein JD. Marijuana and the Pediatric Population. Pediatrics. agosto de 2020;146\(2\):e20192629.](#)

[Babalonis S, Walsh SL. Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. Eur Neuropsychopharmacol. julio de 2020;36:206-16.](#)

[Alves P, Amaral C, Teixeira N, Correia-da-Silva G. Cannabis sativa: Much more beyond  \$\Delta^9\$ -tetrahydrocannabinol. Pharmacol Res. julio de 2020;157:104822.](#)

[Teitel A, Bozimowski G. A Review of the Pharmacology and Anesthetic Implications of Cannabis. AANA J. junio de 2020;88\(3\):237-44.](#)

[Kovalchuk O, Kovalchuk I. Cannabinoids as anticancer therapeutic agents. Cell Cycle. mayo de 2020;19\(9\):961-89.](#)

[Carvalho ACA de, Souza GA de, Marqui SV de, Guiguer ÉL, Araújo AC, Rubira CJ, et al. Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse. Int J Mol Sci. 22 de abril de 2020;21\(8\):E2940.](#)

[Greger J, Bates V, Mechtler L, Gengo F. A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents. J Clin Pharmacol. abril de 2020;60\(4\):432-8.](#)

[Yoo HB, DiMuzio J, Filbey FM. Interaction of Cannabis Use and Aging: From Molecule to Mind. J Dual Diagn. marzo de 2020;16\(1\):140-76.](#)

[Abbott KL, Flannery PC, Gill KS, Boothe DM, Dhanasekaran M, Mani S, et al. Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metab Rev. febrero de 2020;52\(1\):44-65.](#)



[Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. Biomed Res Int. 2020;2020:3902740.](#)

## 2019

[Horvath C, Dalley CB, Grass N, Tola DH. Marijuana Use in the Anesthetized Patient: History, Pharmacology, and Anesthetic Considerations. AANA J. diciembre de 2019;87\(6\):451-8.](#)

[Freeman AM, Petrilli K, Lees R, Hindocha C, Mokrysz C, Curran HV, et al. How does cannabidiol \(CBD\) influence the acute effects of delta-9-tetrahydrocannabinol \(THC\) in humans? A systematic review. Neurosci Biobehav Rev. diciembre de 2019;107:696-712.](#)

[Foster BC, Abramovici H, Harris CS. Cannabis and Cannabinoids: Kinetics and Interactions. Am J Med. noviembre de 2019;132\(11\):1266-70.](#)

[Echeverria-Villalobos M, Todeschini AB, Stoicea N, Fiorda-Diaz J, Weaver T, Bergese SD. Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations. J Clin Anesth. noviembre de 2019;57:41-9.](#)

[Sarzi-Puttini P, Batticciotto A, Atzeni F, Bazzichi L, Di Franco M, Salaffi F, et al. Medical cannabis and cannabinoids in rheumatology: where are we now? Expert Rev Clin Immunol. octubre de 2019;15\(10\):1019-32.](#)

[Qian Y, Gurley BJ, Markowitz JS. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. J Clin Psychopharmacol. octubre de 2019;39\(5\):462-71.](#)

[Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research. Exp Clin Psychopharmacol. agosto de 2019;27\(4\):359-69.](#)

[White CM. A Review of Human Studies Assessing Cannabidiol's \(CBD\) Therapeutic Actions and Potential. J Clin Pharmacol. julio de 2019;59\(7\):923-34.](#)

[Byars T, Theisen E, Bolton DL. Using Cannabis to Treat Cancer-Related Pain. Semin Oncol Nurs. junio de 2019;35\(3\):300-9.](#)

[Cogan PS. On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. Expert Rev Clin Pharmacol. junio de 2019;12\(6\):501-11.](#)

[Cossu AE, Latham LB, Hardacker DM, Jea AH. Pharmacologic chaos: severe hypotension from interactions of anesthetics, marijuana, amphetamines, and paroxetine. J Clin Anesth. 2019;55:17.](#)

[Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritsch M, Pottegård A. Interaction](#)



[between warfarin and cannabis. Basic Clin Pharmacol Toxicol. enero de 2019;124\(1\):28-31.](#)

[Delling FN, Vittinghoff E, Dewland TA, Pletcher MJ, Olgin JE, Nah G, et al. Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open. 15 de mayo de 2019;9\(5\):e027432.](#)

[Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 1 de marzo de 2019;9\(2\):191-203.](#)

[Temple LM, Lampert SL, Ewigman B. Barriers to Achieving Optimal Success with Medical Cannabis: Opportunities for Quality Improvement. J Altern Complement Med. enero de 2019;25\(1\):5-7.](#)

[Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. marzo de 2019;28\(3\):285-96.](#)

[Twardowski MA, Link MM, Twardowski NM. Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures. J Am Osteopath Assoc. 15 de abril de 2019;](#)

## 2018

[Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and  \$\Delta\$ 9-Tetrahydrocannabinol. Neuropsychopharmacology. enero de 2018;43\(1\):142-54.](#)

[Bouquié R, Deslandes G, Mazaré H, Cogné M, Mahé J, Grégoire M, et al. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. Fundam Clin Pharmacol. octubre de 2018;32\(5\):462-84.](#)

[Cannabidiol \(Epidiolex\) for epilepsy. Med Lett Drugs Ther. 5 de noviembre de 2018;60\(1559\):182-4.](#)

[Carlini BH, Garrett SB. Drug helplines and adult marijuana users: An assessment in Washington, Colorado, Oregon, and Alaska. Subst Abus. 02 de 2018;39\(1\):3-5.](#)

[Celius EG, Vila C. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity. Brain Behav. 2018;8\(5\):e00962.](#)

[Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018;43\(10\):2046-55.](#)

[Cosker E, Schwitzer T, Ramoz N, Ligier F, Lalanne L, Gorwood P, et al. The effect of interactions](#)



[between genetics and cannabis use on neurocognition. A review. Prog Neuropsychopharmacol Biol Psychiatry. 02 de 2018;82:95-106.](#)

[de Wit H, Sayette M. Considering the context: social factors in responses to drugs in humans. Psychopharmacology \(Berl\). 2018;235\(4\):935-45.](#)

[Drugs for chronic insomnia. Med Lett Drugs Ther. 17 de diciembre de 2018;60\(1562\):201-5.](#)

[Ecker AH, Buckner JD. Cannabis-Related Problems and Social Anxiety: The Mediation Role of Post-Event Processing. Subst Use Misuse. 02 de 2018;53\(1\):36-41.](#)

[Elvik R. Interpreting interaction effects in estimates of the risk of traffic injury associated with the use of illicit drugs. Accid Anal Prev. abril de 2018;113:224-35.](#)

[Ghovanloo M-R, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 26 de 2018;293\(43\):16546-58.](#)

[Hartberg CB, Lange EH, Lagerberg TV, Haukvik UK, Andreassen OA, Melle I, et al. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. Eur Neuropsychopharmacol. 2018;28\(1\):37-47.](#)

[Heidebrecht F, MacLeod MB, Dawkins L. Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack. Addict Behav. febrero de 2018;77:210-6.](#)

[Hood L. Social Factors and Animal Models of Cannabis Use. Int Rev Neurobiol. 2018;140:171-200.](#)

[Hudson R, Rushlow W, Laviolette SR. Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. Psychopharmacology \(Berl\). 2018;235\(2\):447-58.](#)

[Hughes B, Wiessing L, Des Jarlais D, Griffiths P. Could cannabis liberalisation lead to wider changes in drug policies and outcomes? Int J Drug Policy. 2018;51:156-9.](#)

[Ibera C, Shalom B, Saifi F, Shruder J, Davidson E. \[EFFECTS OF CANNABIS EXTRACT PREMEDICATION ON ANESTHETIC DEPTH\]. Harefuah. marzo de 2018;157\(3\):162-6.](#)

[Iijima R, Watanabe T, Ishiuchi K, Matsumoto T, Watanabe J, Makino T. Interactions between crude drug extracts used in Japanese traditional Kampo medicines and organic anion-transporting polypeptide 2B1. J Ethnopharmacol. 25 de marzo de 2018;214:153-9.](#)

[Klein A, Potter GR. The three betrayals of the medical cannabis growing activist: From multiple victimhood to reconstruction, redemption and activism. Int J Drug Policy. 2018;53:65-72.](#)





[Kong TY, Kim J-H, Kim DK, Lee HS. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. julio de 2018;41\(7\):691-710.](#)

[MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12-9.](#)

[Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 05 de 2018;8\(1\):181.](#)

[Olfson M, Wall MM, Blanco C. Medical Marijuana and the Opioid Epidemic: Response to Theriault and Schlesinger. Am J Psychiatry. 01 de 2018;175\(3\):284-5.](#)

[Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. Biomed Res Int. 2018;2018:1691428.](#)

[Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240-6.](#)

[Rong C, Carmona NE, Lee YL, Raguett R-M, Pan Z, Rosenblat JD, et al. Drug-drug interactions as a result of co-administering  \$\Delta\$ 9-THC and CBD with other psychotropic agents. Expert Opin Drug Saf. 2018;17\(1\):51-4.](#)

[Theriault BM, Schlesinger JJ. Potential Impact of Medical Marijuana on Nonmedical Opioid Use. Am J Psychiatry. 01 de 2018;175\(3\):284.](#)

[Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, et al. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 01 de 2018;182:1-7.](#)

## 2017

[Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. CNS Neurol Disord Drug Targets. 2017;16\(5\):554-66.](#)

[Bagge CL, Borges G. Acute Substance Use as a Warning Sign for Suicide Attempts: A Case-Crossover Examination of the 48 Hours Prior to a Recent Suicide Attempt. J Clin Psychiatry. junio de 2017;78\(6\):691-6.](#)

[Beaulieu P. Anesthetic implications of recreational drug use. Can J Anaesth. diciembre de](#)



[2017;64\(12\):1236-64.](#)

[Deng L, Ng L, Ozawa T, Stella N. Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture. J Pharmacol Exp Ther. enero de 2017;360\(1\):215-24.](#)

[Garin N, Zurita B, Velasco C, Feliu A, Gutierrez M, Masip M, et al. Prevalence and clinical impact of recreational drug consumption in people living with HIV on treatment: a cross-sectional study. BMJ Open. 18 de 2017;7\(1\):e014105.](#)

[Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70\(Pt B\):313-8.](#)

[Hindocha C, Lawn W, Freeman TP, Curran HV. Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology \(Berl\). noviembre de 2017;234\(21\):3153-63.](#)

[Hodgins S, Klein S. New Clinically Relevant Findings about Violence by People with Schizophrenia. Can J Psychiatry. 2017;62\(2\):86-93.](#)

[Lake S, Kerr T, Capler R, Shoveller J, Montaner J, Milloy M-J. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63-70.](#)

[Mahvan TD, Hilaire ML, Mann A, Brown A, Linn B, Gardner T, et al. Marijuana Use in the Elderly: Implications and Considerations. Consult Pharm. 1 de junio de 2017;32\(6\):341-51.](#)

[Marino S, Idris AI. Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacol Res. 2017;119:391-403.](#)

[Martín-Rodríguez MDM, Pulido J, Jiménez-Mejías E, Hoyos J, Lardelli-Claret P, Barrio G. Consistent association between hypnotics/sedatives and non-traffic injuries. Results from a national household survey. Accid Anal Prev. septiembre de 2017;106:379-84.](#)

[Mason BL, Van Enkevort E, Filbey F, Marx CE, Park J, Nakamura A, et al. Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders. J Clin Psychopharmacol. diciembre de 2017;37\(6\):684-8.](#)

[Miró Ò, Galicia M, Dargan P, Dines AM, Giraudon I, Heyerdahl F, et al. Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse. Toxicol Lett. 5 de agosto de 2017;277:84-91.](#)



[O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. \*Epilepsy Behav.\* 2017;70\(Pt B\):341-8.](#)

[Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. \*Epilepsy Behav.\* 2017;70\(Pt B\):319-27.](#)

[Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. \*Curr Neuropharmacol.\* 2017;15\(2\):291-9.](#)

[Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. \*Curr Top Behav Neurosci.\* 2017;32:249-62.](#)

[Thiruchselvam T, Malik S, Le Foll B. A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate. \*Am J Drug Alcohol Abuse.\* 2017;43\(2\):197-214.](#)

[Turgeman I, Bar-Sela G. Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications. \*Isr Med Assoc J.\* febrero de 2017;19\(2\):85-8.](#)

[Volkow ND, Hampson AJ, Baler RD. Don't Worry, Be Happy: Endocannabinoids and Cannabis at the Intersection of Stress and Reward. \*Annu Rev Pharmacol Toxicol.\* 06 de 2017;57:285-308.](#)

[Zaka M, Sehgal SA, Shafique S, Abbasi BH. Comparative in silico analyses of Cannabis sativa, Prunella vulgaris and Withania somnifera compounds elucidating the medicinal properties against rheumatoid arthritis. \*J Mol Graph Model.\* 2017;74:296-304.](#)

[Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. \*Clin Pharmacol Drug Dev.\* marzo de 2017;6\(2\):164-8.](#)

## 2016

[Ali A, Carré A, Hassler C, Spilka S, Vanier A, Barry C, et al. Risk factors for substances use and misuse among young people in France: What can we learn from the Substance Use Risk Profile Scale? \*Drug Alcohol Depend.\* 1 de junio de 2016;163:84-91.](#)

[Anderson GD, Chan L-N. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. \*Clin Pharmacokinet.\* 2016;55\(11\):1353-68.](#)

[Aston ER, Metrik J, Amlung M, Kahler CW, MacKillop J. Interrelationships between marijuana demand and discounting of delayed rewards: Convergence in behavioral economic methods. \*Drug Alcohol Depend.\* 1 de diciembre de 2016;169:141-7.](#)



[Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of  \$\Delta\$ 9-tetrahydrocannabinol on the dopamine system. Nature. 17 de 2016;539\(7629\):369-77.](#)

[Bondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Giroud C. Cannabis and its effects on driving skills. Forensic Sci Int. noviembre de 2016;268:92-102.](#)

[Cannabis and cannabinoids. Med Lett Drugs Ther. 1 de agosto de 2016;58\(1500\):97-8.](#)

[Correia RB, Li L, Rocha LM. MONITORING POTENTIAL DRUG INTERACTIONS AND REACTIONS VIA NETWORK ANALYSIS OF INSTAGRAM USER TIMELINES. Pac Symp Biocomput. 2016;21:492-503.](#)

[Darke S, Farrell M. Which medications are suitable for agonist drug maintenance? Addiction. mayo de 2016;111\(5\):767-74.](#)

[Foster KT, Li N, McClure EA, Sonne SC, Gray KM. Gender Differences in Internalizing Symptoms and Suicide Risk Among Men and Women Seeking Treatment for Cannabis Use Disorder from Late Adolescence to Middle Adulthood. J Subst Abuse Treat. 2016;66:16-22.](#)

[Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal. julio de 2016;8\(7\):690-701.](#)

[Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, et al. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell. 20 de octubre de 2016;167\(3\):750-762.e14.](#)

[Jacobus J, Castro N, Squeglia LM, Meloy MJ, Brumback T, Huestis MA, et al. Adolescent cortical thickness pre- and post marijuana and alcohol initiation. Neurotoxicol Teratol. octubre de 2016;57:20-9.](#)

[Lee MR, Weerts EM. Oxytocin for the treatment of drug and alcohol use disorders. Behav Pharmacol. 2016;27\(8\):640-8.](#)

[Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, et al. From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We? Curr Pharm Des. 2016;22\(42\):6426-33.](#)

[Notzon DP, Mariani JJ, Pavlicova M, Glass A, Mahony AL, Brooks DJ, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Am J Addict. 2016;25\(8\):666-72.](#)

[Ossato A, Canazza I, Trapella C, Vincenzi F, De Luca MA, Rimondo C, et al. Effect of JWH-250, JWH-073 and their interaction on «tetrad», sensorimotor, neurological and neurochemical responses in mice. Prog Neuropsychopharmacol Biol Psychiatry. 3 de junio de 2016;67:31-50.](#)



[Reece AS, Norman A, Hulse GK. Cannabis exposure as an interactive cardiovascular risk factor and accelerant of organismal ageing: a longitudinal study. BMJ Open. 07 de 2016;6\(11\):e011891.](#)

[Ross JM, Graziano P, Pacheco-Colón I, Coxe S, Gonzalez R. Decision-Making Does not Moderate the Association between Cannabis Use and Body Mass Index among Adolescent Cannabis Users. J Int Neuropsychol Soc. 2016;22\(9\):944-9.](#)

[Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biol Psychiatry. 1 de abril de 2016;79\(7\):526-38.](#)

[Volk DW, Lewis DA. The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biol Psychiatry. 1 de abril de 2016;79\(7\):595-603.](#)

## 2015

[Abrams DJ, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. junio de 2015;97\(6\):575-86.](#)

[Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, et al. Monoacylglycerol lipase \(MGLL\) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. J Abnorm Psychol. noviembre de 2015;124\(4\):860-77.](#)

[Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K. \[18F\]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict Biol. marzo de 2015;20\(2\):357-67.](#)

[Clarke DE, Gonzalez M, Pereira A, Boyce-Gaudreau K, Waldman C, Demczuk L. The impact of knowledge on attitudes of emergency department staff towards patients with substance related presentations: a quantitative systematic review protocol. JBI Database System Rev Implement Rep. octubre de 2015;13\(10\):133-45.](#)

[Cochran G, Stitzer M, Campbell ANC, Hu M-C, Vandrey R, Nunes EV. Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav. junio de 2015;45:191-4.](#)

[D'Souza DC, Ranganathan M. Medical Marijuana: Is the Cart Before the Horse? JAMA. 23 de junio de 2015;313\(24\):2431-2.](#)

[Felton D, Zitomersky N, Manzi S, Lightdale JR. 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire. Pediatrics. abril de 2015;135\(4\):e1060-1063.](#)

[Filbey FM, McQueeney T, Kadamangudi S, Bice C, Ketcherside A. Combined effects of marijuana and nicotine on memory performance and hippocampal volume. Behav Brain Res. 15 de octubre de](#)



[2015;293:46-53.](#)

[Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. \*Epilepsia\*. agosto de 2015;56\(8\):1246-51.](#)

[Geresu B. Khat \(\*Catha edulis\* F.\) and cannabinoids: Parallel and contrasting behavioral effects in preclinical and clinical studies. \*Pharmacol Biochem Behav\*. noviembre de 2015;138:164-73.](#)

[Goodman J, Packard MG. The influence of cannabinoids on learning and memory processes of the dorsal striatum. \*Neurobiol Learn Mem\*. noviembre de 2015;125:1-14.](#)

[Grant JD, Waldron M, Sartor CE, Scherrer JF, Duncan AE, McCutcheon VV, et al. Parental Separation and Offspring Alcohol Involvement: Findings from Offspring of Alcoholic and Drug Dependent Twin Fathers. \*Alcohol Clin Exp Res\*. julio de 2015;39\(7\):1166-73.](#)

[Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, et al. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. \*Clin Chem\*. junio de 2015;61\(6\):850-69.](#)

[Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving lateral control with and without alcohol. \*Drug Alcohol Depend\*. 1 de septiembre de 2015;154:25-37.](#)

[Hindochoa C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJA, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. \*Eur Neuropsychopharmacol\*. marzo de 2015;25\(3\):325-34.](#)

[Karoly HC, Bryan AD, Weiland BJ, Mayer A, Dodd A, Feldstein Ewing SW. Does incentive-elicited nucleus accumbens activation differ by substance of abuse? An examination with adolescents. \*Dev Cogn Neurosci\*. diciembre de 2015;16:5-15.](#)

[Kollins SH, Schoenfelder EN, English JS, Holdaway A, Van Voorhees E, O'Brien BR, et al. An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol \(THC\) on cardiovascular function, subjective effects, and performance in healthy adults. \*J Subst Abuse Treat\*. enero de 2015;48\(1\):96-103.](#)

[Lamy S, Laqueille X, Thibaut F. \[Consequences of tobacco, cocaine and cannabis consumption during pregnancy on the pregnancy itself, on the newborn and on child development: A review\]. \*Encephale\*. junio de 2015;41 Suppl 1:S13-20.](#)

[Le Roux G, Bruneau C, Lelièvre B, Bretaudeau Deguigne M, Turcant A, Harry P, et al. Recreational phenethylamine poisonings reported to a French poison control center. \*Drug Alcohol Depend\*. 1](#)



[de septiembre de 2015;154:46-53.](#)

[Lee TT-Y, Gorzalka BB. Evidence for a Role of Adolescent Endocannabinoid Signaling in Regulating HPA Axis Stress Responsivity and Emotional Behavior Development. Int Rev Neurobiol. 2015;125:49-84.](#)

[McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 1 de noviembre de 2015;156:29-37.](#)

[Metz TD, Stickrath EH. Marijuana use in pregnancy and lactation: a review of the evidence. Am J Obstet Gynecol. diciembre de 2015;213\(6\):761-78.](#)

[Miovský M, Voňková H, Gabrhelík R, Šťastná L. Universality properties of school-based preventive intervention targeted at cannabis use. Prev Sci. febrero de 2015;16\(2\):189-99.](#)

[Moeller SJ, Beebe-Wang N, Schneider KE, Konova AB, Parvaz MA, Alia-Klein N, et al. Effects of an opioid \(proenkephalin\) polymorphism on neural response to errors in health and cocaine use disorder. Behav Brain Res. 15 de octubre de 2015;293:18-26.](#)

[Newville H, Berg KM, Gonzalez JS. The interaction of active substance use, depression, and antiretroviral adherence in methadone maintenance. Int J Behav Med. abril de 2015;22\(2\):214-22.](#)

[Nielsen MKK, Johansen SS, Linnet K. Evaluation of poly-drug use in methadone-related fatalities using segmental hair analysis. Forensic Sci Int. marzo de 2015;248:134-9.](#)

[Peeters SCT, van Bronswijk S, van de Ven V, Gronenschild EHBM, Goebel R, van Os J, et al. Cognitive correlates of frontoparietal network connectivity «at rest» in individuals with differential risk for psychotic disorder. Eur Neuropsychopharmacol. noviembre de 2015;25\(11\):1922-32.](#)

[Peeters SCT, van de Ven V, Gronenschild EHBM, Patel AX, Habets P, Goebel R, et al. Default mode network connectivity as a function of familial and environmental risk for psychotic disorder. PLoS ONE. 2015;10\(3\):e0120030.](#)

[Price JS, McQueeney T, Shollenbarger S, Browning EL, Wieser J, Lisdahl KM. Effects of marijuana use on prefrontal and parietal volumes and cognition in emerging adults. Psychopharmacology \(Berl\). agosto de 2015;232\(16\):2939-50.](#)

[Schneider R, Ottoni GL, de Carvalho HW, Elisabetsky E, Lara DR. Temperament and character traits associated with the use of alcohol, cannabis, cocaine, benzodiazepines, and hallucinogens: evidence from a large Brazilian web survey. Braz J Psychiatry. marzo de 2015;37\(1\):31-9.](#)

[Schuster RM, Crane NA, Mermelstein R, Gonzalez R. Tobacco may mask poorer episodic memory](#)



[among young adult cannabis users. Neuropsychology. septiembre de 2015;29\(5\):759-66.](#)

[Subbaraman MS, Kerr WC. Simultaneous versus concurrent use of alcohol and cannabis in the National Alcohol Survey. Alcohol Clin Exp Res. mayo de 2015;39\(5\):872-9.](#)

[Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. enero de 2015;16\(1\):9-18.](#)

[Tormey WP. Newspaper reports from the Coroners Court in Ireland are used to reveal the potential complexity and need for reform in forensic toxicology and medicine services. J Forensic Leg Med. mayo de 2015;32:47-52.](#)

[Wøien V-A, Horwitz H, Høgberg LCG, Askaa B, Jürgens G. \[Cannabis--abuse and consequences\]. Ugeskr Laeg. 2 de febrero de 2015;177\(6\).](#)

## 2014

[Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. junio de 2014;55\(6\):787-90.](#)

[Davis GP, Surratt HL, Levin FR, Blanco C. Antiretroviral medication: an emerging category of prescription drug misuse. Am J Addict. diciembre de 2014;23\(6\):519-25.](#)

[Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis. Prescrire Int. junio de 2014;23\(150\):145-8.](#)

[Lile JA, Kelly TH, Hays LR. Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ9-THC in humans discriminating Δ9-THC. Drug Alcohol Depend. 1 de octubre de 2014;143:141-8.](#)

[O'Tuathaigh CMP, Gantois I, Waddington JL. Genetic dissection of the psychotomimetic effects of cannabinoid exposure. Prog Neuropsychopharmacol Biol Psychiatry. 3 de julio de 2014;52:33-40.](#)

[Richardson P. The Case of the cannabis conundrum. ONS Connect. diciembre de 2014;29\(4\):11.](#)





## OTRAS PUBLICACIONES



### [Therapeutic Use of Medical Cannabis in New York State \[Internet\].](#)

Slawek D, Arnsten JH, Whitley SD, et al.  
Baltimore (MD): Johns Hopkins University; 2022.



### [Medicinal Cannabis: Pearls for Clinical Practice](#)

Deborah Malka  
CRC Press; 2021.



### [Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain \[Internet\].](#)

McDonagh MS, Wagner J, Ahmed AY, et al.  
Rockville (MD): Agency for Healthcare Research and Quality (US); 2021.  
(Comparative Effectiveness Review, No. 250.)


[Table of Contents](#)



### [Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Interim Progress Reports \[Internet\].](#)

Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.

[Table of Contents](#)



### [Medicalization of marijuana: legitimacy, stigma, and the patient experience](#)

Newhart M, Dolphin W  
Routledge; 2019.



GOBIERNO DE ESPAÑA

MINISTERIO DE SANIDAD

SECRETARÍA DE ESTADO DE DROGAS

DELEGACIÓN DEL GOBIERNO PARA EL PLAN NACIONAL SOBRE DROGAS

## Delegación del Gobierno para el Plan Nacional sobre Drogas



Centro de documentación:  
Publicaciones




Posibles Usos Terapéuticos

Contacto



### [Cannabis as Medicine](#)

Betty Wedman-St.Louis  
CRC Press; 2019.



### [Therapeutic Uses of Cannabis](#)

British Medical Association  
CRC Press; 2019.



### [The Use of Medical Cannabis with Other Medications: A Review of Safety and Guidelines - An Update \[Internet\].](#)

MacDonald E, Adams A.  
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.  
[Table of Contents](#)



### [Medical Cannabis Use in Palliative Care: Review of Clinical Effectiveness and Guidelines - An Update \[Internet\].](#)

MacDonald E, Farrah K.  
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.  
[Table of Contents](#)



### [Uso médico del cannabis y los cannabinoides: preguntas y respuestas para la formulación de políticas](#)

EMCDDA; 2018.